For this we first compared all patients high for CAMK2N1 and low for SCGB2A1, with reduced expression of 3–4 progressor genes (N = 25 patients diagnosed with IDC; N = 7 patients with Pure DCIS). This evidence concerns the gene SCGB2A1 and ductal breast carcinoma in situ.